Chemical Compound Review:
Darfenacin 2-[1-[2-(2,3- dihydrobenzofuran-5...
Synonyms:
darifenicin, SureCN113331, ANW-57645, CHEBI:431080, AC1L2HBG, ...
Cardozo,
Dixon,
Michel,
Hegde,
Parsons,
Robinson,
Cardozo,
Bockman,
Bradley,
Dang,
Zeng,
Scofield,
Dowd,
Lipton,
Kolodner,
Wesnes,
Kerbusch,
Wählby,
Milligan,
Karlsson,
Chapple,
Steers,
Norton,
Millard,
Kralidis,
Glavind,
Abrams,
Kershen,
Hsieh,
Kay,
Wesnes,
Kobayashi,
Ikeda,
Suzuki,
Yamada,
Miyata,
Ohtake,
Ukai,
Hatanaka,
Kobayashi,
Ikeda,
Sato,
Miyata,
Sasamata,
Rosario,
Smith,
Radley,
Chapple,
Skerjanec,
Hegde,
Ikeda,
Kobayashi,
Suzuki,
Miyata,
Takeuchi,
Yamada,
Honda,
- The clinical pharmacokinetics of darifenacin. Skerjanec, A. Clinical pharmacokinetics. (2006)
- Muscarinic receptors in the bladder: from basic research to therapeutics. Hegde, S.S. Br. J. Pharmacol. (2006)
- The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction. Pontari, M.A., Braverman, A.S., Ruggieri, M.R. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2004)
- Assessment of cognitive function of the elderly population: effects of darifenacin. Lipton, R.B., Kolodner, K., Wesnes, K. J. Urol. (2005)
- Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder. Oki, T., Kageyama, A., Takagi, Y., Uchida, S., Yamada, S. J. Urol. (2007)
- In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Ohtake, A., Ukai, M., Hatanaka, T., Kobayashi, S., Ikeda, K., Sato, S., Miyata, K., Sasamata, M. Eur. J. Pharmacol. (2004)
- Treatment of the overactive bladder syndrome with muscarinic receptor antagonists - a matter of metabolites? Michel, M.C., Hegde, S.S. Naunyn Schmiedebergs Arch. Pharmacol. (2006)
- Preview of new drugs for overactive bladder and incontinence: darifenacin, solifenacin, trospium, and duloxetine. Kershen, R.T., Hsieh, M. Current urology reports. (2004)
- Constitutive activity and inverse agonism at the M2 muscarinic acetylcholine receptor. Nelson, C.P., Nahorski, S.R., Challiss, R.A. J. Pharmacol. Exp. Ther. (2006)
- Muscarinic receptor subtypes in the human colon: lack of evidence for atypical subtypes. Mansfield, K.J., Mitchelson, F.J., Moore, K.H., Burcher, E. Eur. J. Pharmacol. (2003)
- Pharmacodynamics of anticholinergic agents measured by ambulatory urodynamic monitoring: a study of methodology. Rosario, D.J., Smith, D.J., Radley, S.C., Chapple, C.R. Neurourology and urodynamics. (1999)
- Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Kerbusch, T., Wählby, U., Milligan, P.A., Karlsson, M.O. British journal of clinical pharmacology. (2003)
- Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists. Gillberg, P.G., Sundquist, S., Nilvebrant, L. Eur. J. Pharmacol. (1998)
- Functional selectivity of muscarinic receptor antagonists for inhibition of M3-mediated phosphoinositide responses in guinea pig urinary bladder and submandibular salivary gland. Nelson, C.P., Gupta, P., Napier, C.M., Nahorski, S.R., Challiss, R.A. J. Pharmacol. Exp. Ther. (2004)
- Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Mansfield, K.J., Liu, L., Mitchelson, F.J., Moore, K.H., Millard, R.J., Burcher, E. Br. J. Pharmacol. (2005)
- Molecular and pharmacological characterization of muscarinic receptor subtypes in a rat parotid gland cell line: comparison with native parotid gland. Bockman, C.S., Bradley, M.E., Dang, H.K., Zeng, W., Scofield, M.A., Dowd, F.J. J. Pharmacol. Exp. Ther. (2001)
- M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Ikeda, K., Kobayashi, S., Suzuki, M., Miyata, K., Takeuchi, M., Yamada, T., Honda, K. Naunyn Schmiedebergs Arch. Pharmacol. (2002)
- M2 and M3 muscarinic receptor activation of urinary bladder contractile signal transduction. II. Denervated rat bladder. Braverman, A.S., Doumanian, L.R., Ruggieri, M.R. J. Pharmacol. Exp. Ther. (2006)
- Pharmacological effects of darifenacin on human isolated urinary bladder. Miyamae, K., Yoshida, M., Murakami, S., Iwashita, H., Ohtani, M., Masunaga, K., Ueda, S. Pharmacology (2003)
- Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. Kay, G.G., Wesnes, K.A. BJU international. (2005)
- A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. Chapple, C., Steers, W., Norton, P., Millard, R., Kralidis, G., Glavind, K., Abrams, P. BJU international. (2005)
- Effects of YM905, a novel muscarinic M3-receptor antagonist, on experimental models of bowel dysfunction in vivo. Kobayashi, S., Ikeda, K., Suzuki, M., Yamada, T., Miyata, K. Jpn. J. Pharmacol. (2001)
- Darifenacin in the treatment of overactive bladder. Parsons, M., Robinson, D., Cardozo, L. International journal of clinical practice. (2005)
- Rapid, solid phase extraction technique for the high-throughput assay of darifenacin in human plasma. Kaye, B., Herron, W.J., Macrae, P.V., Robinson, S., Stopher, D.A., Venn, R.F., Wild, W. Anal. Chem. (1996)
- Increased warning time with darifenacin: a new concept in the management of urinary urgency. Cardozo, L., Dixon, A. J. Urol. (2005)
- Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. Foote, J., Glavind, K., Kralidis, G., Wyndaele, J.J. Eur. Urol. (2005)